Literature DB >> 412648

Antimicrobial synergism in the therapy of gram-negative rod bacteremia.

E T Anderson, L S Young, W L Hewitt.   

Abstract

To determine if antimicrobial synergism might affect the results of treatment of gram-negative rod infections, 444 bacteremias from 1972 through 1974 were studied. On these, 173 were treated with two antibiotics to which the infecting organisms were sensitive. Clinical responses were observed in 80% of 83 cases where antibiotic activity was synergistic, as defined by a minimum inhibitory concentration (MIC) of each antibiotic in combination being one-fourth or less than the MICs of individual drugs. This response rate was significantly better than the 64% response seen in patients treated with nonsynergistic combinations (p less than 0.05). Synergism correlated with significantly better clinical responses in those patients with "rapidly fatal" and "ultimately fatal" underlying disease (p less than 0.005), neutropenia (p less than 0.001), shock (p less than 0.01) and Pseudomonas aeruginosa infections (p less than 0.05). These results suggest that the use of antibiotic combinations to treat patients with gram-negative rod bacteremia who have the poorest prognosis is clinically justified and the improved results may be related to the synergistic activity of antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 412648     DOI: 10.1159/000237759

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  42 in total

1.  In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa.

Authors:  M D Lyon; K R Smith; M S Saag; G A Cloud; C G Cobbs
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

Review 2.  Antimicrobial agent therapy for Pseudomonas aeruginosa.

Authors:  J A Korvick; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

3.  In vitro activity of aztreonam, cefotaxime, ceftazidime and imipenem combined with ciprofloxacin against gram-negative bacilli and compared with amikacin combinations against Pseudomonas aeruginosa.

Authors:  M Díez Enciso
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-02       Impact factor: 3.267

4.  Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test.

Authors:  R L White; D S Burgess; M Manduru; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 5.  Antibiotic combinations: should they be tested?

Authors:  G M Eliopoulos; C T Eliopoulos
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

6.  Empiric antimicrobial therapy in severe sepsis and septic shock: optimizing pathogen clearance.

Authors:  Stephen Y Liang; Anand Kumar
Journal:  Curr Infect Dis Rep       Date:  2015-07       Impact factor: 3.725

7.  Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.

Authors:  M Joshi; W C Anthony; J H Tenney; G L Drusano; E S Caplan; H C Standiford; A Henson; J W Warren
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

8.  Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients.

Authors:  J Klastersky; M P Glauser; S C Schimpff; S H Zinner; H Gaya
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

9.  In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli.

Authors:  M A Buesing; J H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

10.  Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

Authors:  J Klastersky; L Coppens; F Meunier-Carpentier; A P Menday
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.